Daratumumab FDA Approved for Transplant-Eligible Patients With Multiple Myeloma

The FDA has now approved daratumumab (Darzalex®, Janssen) to be used in combination with bortezomib, thalidomide, and dexamethasone (VTd) in adult patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant. Daratumumab, a targeted monoclonal antibody, works by attaching itself to a protein called CD38 on multiple myeloma cells. This either directly kills the multiple myeloma cells or allows the body to identify these cells as a foreign invader, therefo...
Continue reading

Multiple Myeloma Transcriptome Reveals New Treatment Targets

Although targeted therapies have improved survival for patients with multiple myeloma, relapse still occurs. One hypothesis regarding why relapse happens is that the skeleton provides a niche in which dormant myeloma cells can hide. When scientists testing this hypothesis identified a strategy to sequence the transcriptome of individual dormant myeloma cells from the bones of tumor-ridden mice, they discovered that a specific transcriptome expressed by myeloma cells enriches immune genes and mye...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.